MNKD Key Stats
- MannKind: Follow The Smart Money Yahoo 03/10 12:48 ET
- MANNKIND CORP Financials Yahoo 03/08 13:04 ET
- How Will Subconscious Issues Influence FDA AdCom Voting On Afrezza? Yahoo 03/06 12:11 ET
- April 25th Options Now Available For MannKind (MNKD) Yahoo 03/06 11:06 ET
- Biotech Stock Mailbag Extra: MannKind's Afrezza Panel Setup Yahoo 03/06 10:14 ET
- Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics Yahoo 03/04 14:01 ET
- MannKind's Management Presents at Cowen and Company 34th Annual Health Care Conference (Transcript) Seeking Alpha 03/03 19:30 ET
- MannKind (MNKD) Discloses $50M ATM Common Stock Sales Agreement Street Insider 03/03 16:51 ET
- MANNKIND CORP Files SEC form 10-K, Annual Report Yahoo 03/03 16:37 ET
- A Busy Calendar of March Biotech Events The Street 03/03 08:13 ET
MNKD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). MannKind is up 84.64% over the last year vs S&P 500 Total Return up 24.21%, Actelion up 104.6%, and Alexion Pharmaceuticals up 93.21%.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for MNKD
Pro Report PDF for MNKD
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download MNKD Pro Report PDF
Pro Strategies Featuring MNKD
Did MannKind make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
MannKind Corporation is engaged in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.